RALEIGH, N.C., June 19, 2017 -- As part of its new Center for Pediatric Clinical Development initiative, PRA Health Sciences is pleased to announce its partnership with Jumo. Jumo is an award-winning provider of educational health care information and resources for children, families, and caregivers.
“We are excited about this partnership,” said Mark Sorrentino, Vice President, The Center for Pediatric Clinical Development. “When it comes to pediatric clinical trials, we know that patients and caregivers are fearful and there is often a lack of understanding of what to expect. Jumo’s novel materials aid in the education and engagement of these trials.”
PRA’s new Center for Pediatric Clinical Development which was announced earlier this year is looking to bring innovation to pediatric clinical trial design and implementation and to facilitate patient recruitment.
“We look forward to collaborating with PRA and finding new and innovative ways to assist young patients and their families and to help them remain engaged and motivated in clinical trials,” said Kate Hersov, Founder, Jumo. “Working with investigators and other health care professionals, we pride ourselves on our ability to provide age-appropriate materials that help empower patients and caregivers and deliver positive and successful outcomes and trial experiences.”
A provider of consulting services as well as experienced technical and operational services, The Center for Pediatric Clinical Development team connects PRA’s pediatric expertise across functional areas into a single global resource to support all aspects of client needs related to pediatric product development.
ABOUT PRA HEALTH SCIENCES
PRA (NASDAQ:PRAH) is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and over 13,300 employees worldwide. Since 2000, PRA has performed approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com.
ABOUT JUMO
Jumo is a global health care education company with offices in New York, London, and Sydney. Founded by a doctor who wanted to alleviate the fear and uncertainty of children that often accompanies a clinical diagnosis, Jumo creates comic books, videos, podcasts, and apps that help children and their families better understand and manage their health and wellness. Our products provide individuals with the ability to learn in their way, on their terms, throughout their medical journey. To learn more about Jumo, please visit www.JumoHealth.com.
MEDIA INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463 INVESTOR INQUIRIES: [email protected]


China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 



